FDA的批准基于CASSIOPEIA试验的数据，该试验评估了daratumumab联合VTD在新诊断的MM患者中的疗效。数据表明，联合治疗在患者中表现出显著的临床获益。同时，一些因素可能会影响治疗效果，如患者的体能状态、疾病分期以及治疗过程中的并发症等。六、并发症或不良反应及解决措施 尽管daratumumab联合VTD显示出较好的疗效，但仍可能...
Daratumumab (DARA) is the biological name of an Immunoglobulin G1k human monoclonal antibody. DARA the first-in-class therapy targeting CD38 expressing- plasma cells (PC) and plasma blasts. It has been approved for the treatment of multiple myeloma. It is also being examined in the setting of...
Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT.
[1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent...
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. PMID: 34192431 Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. PMID: 27557302 Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. PMID: 31141632
1. Johnson & Johnson submits supplemental biologics license application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma. News release. Johnson & Johnson. Janu...
Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myelomaCyrille TouzeauBenjamin HébraudXavier Leleu
single agent has been found to be effective in relapsed and refractory myeloma patients, and according to these results, the main objective of this phase 1 trial has been to combine this monoclonal antibody with different backbone reg...
89%的患者对来那度胺耐药,71%的患者对硼替佐米(bortezomib)耐药,64%的患者对硼替佐米和来那度胺耐药。 参考文献: [1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网...